<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK547920" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK547920/" /><meta name="ncbi_pagename" content="Tetracycline - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Tetracycline - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Tetracycline" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/06/10" /><meta name="citation_pmid" content="31643255" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547920/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Tetracycline" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/06/10" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547920/" /><meta name="description" content="Tetracycline is an oral, broad-spectrum antibiotic used to treat mild-to-moderate infections due to susceptible microbial organisms. High doses of several forms of tetracycline given intravenously have been associated with acute fatty liver that can be severe and result in liver failure and death. Oral tetracycline use has been rarely and not very convincingly linked to acute hepatic injury." /><meta name="og:title" content="Tetracycline" /><meta name="og:type" content="book" /><meta name="og:description" content="Tetracycline is an oral, broad-spectrum antibiotic used to treat mild-to-moderate infections due to susceptible microbial organisms. High doses of several forms of tetracycline given intravenously have been associated with acute fatty liver that can be severe and result in liver failure and death. Oral tetracycline use has been rarely and not very convincingly linked to acute hepatic injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547920/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/TetracyclineAndOxyte/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547920/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D98FA0466D2110000000008F50292.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK547920_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK547920_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Tesamorelin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Tetracyclines/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK547920_"><span class="title" itemprop="name">Tetracycline</span></h1><p class="small">Last Update: <span itemprop="dateModified">June 10, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="TetracyclineAndOxyte.OVERVIEW"><h2 id="_TetracyclineAndOxyte_OVERVIEW_">OVERVIEW</h2><div id="TetracyclineAndOxyte.Introduction"><h3>Introduction</h3><p>Tetracycline is an oral, broad-spectrum antibiotic used to treat mild-to-moderate infections due to susceptible microbial organisms. High doses of several forms of tetracycline given intravenously have been associated with acute fatty liver that can be severe and result in liver failure and death. Oral tetracycline use has been rarely and not very convincingly linked to acute hepatic injury.</p></div><div id="TetracyclineAndOxyte.Background"><h3>Background</h3><p>Tetracycline is an oral, broad-spectrum antibiotic and semisynthetic derivative of Streptomyces actinobacteria. Tetracycline acts by inhibition of protein synthesis by binding to the 30S subunit of microbial ribosomes. Human cells are less susceptible to this inhibition. Tetracycline was first approved for use in the United States in 1957 and was one of several oral tetracyclines used at that time (oxytetracycline, chlortetracycline), many of which are no longer available or are used in veterinary medicine only. More modern forms of tetracycline include doxycycline and minocycline which are much more commonly used and have similar indications. Currently, tetracycline is most frequently used for upper respiratory and skin and soft tissue infection and more than 2 million prescriptions are filled yearly. Chronic therapy with tetracycline is effective in ameliorating acne, but because of their better absorption and tissue penetration, minocycline and doxycycline have largely replaced tetracycline for this indication. Tetracycline is also active against infections with several rickettsial, spirochetal, chlamydial and mycoplasmas infections and are often used for therapy of nonspecific urethritis and several Rickettsia diseases, such as Rocky Mountain spotted fever and Lyme disease. Tetracycline is available in multiple generic forms as capsules or tablets of 250 and 500 mg and generally recommended in doses of 250 to 500 mg three to four times daily for 7 to 30 days. Chronic therapy is typical for therapy of acne. Pediatric formulations as oral suspension are also available. Parenteral tetracycline is no longer used. Common side effects include gastrointestinal upset, nausea, poor appetitle, diarrhea, glossitis, rash and hypersensitivity reactions. Tetracycline can cause staining of developing teeth (in children or when taken by a pregnant mother).</p></div><div id="TetracyclineAndOxyte.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>High doses of intravenous tetracycline can induce fatty liver disease and may result in severe hepatic dysfunction, acute liver failure and death. This syndrome is more common among pregnant women, largely during the last trimester or early postpartum period. However, instances of acute fatty liver attributed to intravenous tetracycline have been reported in nonpregnant women and in men and even in children. The injury is characterized by onset of weakness, fever, fatigue, nausea and abdominal pain after 3 to 10 days of therapy. Laboratory tests show minimal-to-moderate elevations in serum aminotransferase and alkaline phosphatase levels with mild jaundice, but presence of hyperammonemia and coagulopathy. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.pancreatitis/">Pancreatitis</a>, renal dysfunction and lactic acidosis are also common, although not always specifically sought. The syndrome may be reversible if tetracycline is stopped promptly, but it is usually recognized late and can progress to multiorgan failure and death despite stopping the agent. This syndrome also occurs with high doses of intravenous doxycycline and minocycline, but quite rarely. This syndrome is rarely seen currently as tetracycline is no longer available in parenteral form and the use of intravenous tetracyclines has been superseded by availability of safer, better tolerated and more effective broad spectrum antibiotics.</p><p>Oral tetracycline has been associated with rare instances of acute liver injury, but the association with tetracycline use as opposed to other agents being taken has not always been very well shown. Despite frequency of its use, oral tetracycline remains a very rare cause of liver injury. In contrast, cases of doxycycline and minocycline induced liver disease are well described. Rare instances of acute fatty liver have been attributed to oral tetracycline, particularly when given to pregnant women in high doses. Currently, tetracycline is considered contraindicated in pregnant women, particularly during the last trimester.</p><p>Likelihood score: A[HD] (well known cause of clinically apparent liver injury but usually when given in high doses intravenously).</p></div><div id="TetracyclineAndOxyte.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The hepatic injury from intravenous forms of tetracycline was likely due to mitochondrial injury due to inhibition of mitochondrial protein synthesis, although another possibility is that tetracycline interferes with fat metabolism in hepatocytes. The injury is less idiosyncratic than direct, varying in frequency and severity based upon pharmacokinetics and host metabolic factors (age, pregnancy, drug accumulation, and other factors affecting mitochondrial function). The rare idiosyncratic forms of liver injury from tetracycline are of unknown cause, but are likely to be immunoallergic.</p></div><div id="TetracyclineAndOxyte.Outcome_and_Managem"><h3>Outcome and Management</h3><p><a class="def" href="/books/n/livertox/glossary/def-item/glossary.acute-fatty-liver/">Acute fatty liver</a> due to tetracycline has a high fatality rate and is best managed with intensive care and attention to multiorgan support. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.lactic-acidosis/">Lactic acidosis</a> should be treated with intravenous glucose (20% infusions) and bicarbonate. Idiosyncratic acute liver injury from tetracycline is rare and usually resolves rapidly once the agent is withdrawn. An instance of chronic cholestasis with vanishing bile duct syndrome has been reported, although the patient had received several medications that might have accounted for the hepatic injury.</p><p>Drug Class: <a href="/books/n/livertox/Antiinfective/">Antiinfective Agents</a>, <a href="/books/n/livertox/Tetracyclines/">Tetracyclines</a></p></div></div><div id="TetracyclineAndOxyte.CASE_REPORT"><h2 id="_TetracyclineAndOxyte_CASE_REPORT_">CASE REPORT</h2><div id="TetracyclineAndOxyte.Case_1._Liver_failu"><h3>Case 1. Liver failure from intravenous tetracycline.</h3><p>[Modified from: Robinson MJ, Rywlin AM. Tetracycline-associated fatty liver in the male. Report of an autopsied case. Am J Dig Dis 1970; 15: 857-62. <a href="https://www.ncbi.nlm.nih.gov/pubmed/5459744" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 72 year old man treated for cystitis and diverticulitis with 10 days of iv tetracycline developed lactic acidosis and multiorgan failure. The patient had no previous history of liver disease or risk factors for hepatitis. When initially admitted to the hospital, he had fever, abdominal pain, leukocytosis and an abnormal urinalysis, but liver tests were normal (Table). He was treated with hydration and iv tetracycline in doses of 3 grams daily. His fever improved slowly, but by day 4, liver tests were mildly abnormal and they had worsened by day 8. Colistin was added on day 6, and chloramphenicol was substituted for tetracycline on day 10. The following day, he developed progressive restlessness, stupor and respiratory failure. He had renal failure and severe acidosis and he died within hours of attempting resuscitation and dialysis. Autopsy showed an enlarged fatty liver with minimal inflammation and no obvious hepatocellular necrosis. Fat was also identified in renal tubular cells. There was marked ascites and hemorrhagic pancreatitis.</p><div id="TetracyclineAndOxyte.Key_Points"><h4>Key Points</h4><div id="TetracyclineAndOxyte.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547920/table/TetracyclineAndOxyte.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__TetracyclineAndOxyte.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Tetracycline (3 g iv daily for 10 days)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">5+ (death from hepatic failure and lactic acidosis)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">4 days</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Fatal</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Colistin and chloramphenicol (after onset of liver injury)</td></tr></tbody></table></div></div></div><div id="TetracyclineAndOxyte.Laboratory_Values"><h4>Laboratory Values</h4><div id="TetracyclineAndOxyte.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547920/table/TetracyclineAndOxyte.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__TetracyclineAndOxyte.T2_lrgtbl__"><table><thead><tr><th id="hd_h_TetracyclineAndOxyte.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_TetracyclineAndOxyte.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_TetracyclineAndOxyte.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_TetracyclineAndOxyte.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P* (U/L)</th><th id="hd_h_TetracyclineAndOxyte.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_TetracyclineAndOxyte.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">32</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">8</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.3</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Started iv tetracycline</td></tr><tr><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 days</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">190</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">10</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.4</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">BUN 39 mg/dL</td></tr><tr><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 days</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">530</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">11.5</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.2</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Colistin added im q 12 hr</td></tr><tr><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">10 days</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_3 hd_h_TetracyclineAndOxyte.T2_1_1_1_4 hd_h_TetracyclineAndOxyte.T2_1_1_1_5 hd_h_TetracyclineAndOxyte.T2_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Tetracycline stopped; chloramphenicol started.</td></tr><tr><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">11 days</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">1 day</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1550</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">15</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">6.8</td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">BUN 105; CO2 11 mEq/L</td></tr><tr><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_1 hd_h_TetracyclineAndOxyte.T2_1_1_1_2 hd_h_TetracyclineAndOxyte.T2_1_1_1_3 hd_h_TetracyclineAndOxyte.T2_1_1_1_4 hd_h_TetracyclineAndOxyte.T2_1_1_1_5 hd_h_TetracyclineAndOxyte.T2_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Increasing stupor and respiratory failure, hemodialysis and resuscitative measures failed.</td></tr><tr><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_1 hd_h_TetracyclineAndOxyte.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;13</b></td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_TetracyclineAndOxyte.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>* King Armstrong units</p></div><div id="TetracyclineAndOxyte.Comment"><h4>Comment</h4><p><a class="def" href="/books/n/livertox/glossary/def-item/glossary.acute-fatty-liver/">Acute fatty liver</a> caused by tetracycline was initially thought to occur only in pregnant women during the last trimester, but was subsequently reported to occur at other times during pregnancy, after delivery, in nonpregnant women, in men and even in children. The syndrome typically occurs after 3 to 10 days of relatively high doses of im or iv tetracycline. The case above is typical in demonstrating that the precipitous onset of symptoms is a late phenomenon and has a grim prognosis; symptoms are preceded by several days of worsening liver injury, although laboratory tests may be only mildly or moderately abnormal. Acute fatty liver is accompanied by minimal hepatic inflammation and liver cell necrosis and is a syndrome of mark mitochondrial failure, early appearance of hepatic synthetic dysfunction and lack of <a class="def" href="/books/n/livertox/glossary/def-item/glossary.adenosine-triphosphate-atp-/">ATP</a> to drive normal metabolism. The injury is not confined to the liver, and renal failure and pancreatitis are common. As in this case, the immediate cause of death is typically multiorgan failure due to lactic acidosis or pancreatitis.</p></div></div></div><div id="TetracyclineAndOxyte.PRODUCT_INFORMATION"><h2 id="_TetracyclineAndOxyte_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="TetracyclineAndOxyte.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Tetracycline &#x02013; Generic, Sumycin&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiinfective Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=tetracyclines" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="TetracyclineAndOxyte.CHEMICAL_FORMULA_AN"><h2 id="_TetracyclineAndOxyte_CHEMICAL_FORMULA_AN_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="TetracyclineAndOxyte.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547920/table/TetracyclineAndOxyte.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__TetracyclineAndOxyte.T3_lrgtbl__"><table><thead><tr><th id="hd_h_TetracyclineAndOxyte.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_TetracyclineAndOxyte.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_TetracyclineAndOxyte.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_TetracyclineAndOxyte.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_TetracyclineAndOxyte.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Tetracycline<br /> Hydrochloride</td><td headers="hd_h_TetracyclineAndOxyte.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134972302" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">64-75-5</a></td><td headers="hd_h_TetracyclineAndOxyte.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C22-H24-N2-O8.Cl-H</td><td headers="hd_h_TetracyclineAndOxyte.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK547920/bin/Tetracycline_hydrochloride.jpg" alt="Tetracycline hydrochloride chemical structure" /></div></td></tr></tbody></table></div></div></div><div id="TetracyclineAndOxyte.ANNOTATED_BIBLIOGRA"><h2 id="_TetracyclineAndOxyte_ANNOTATED_BIBLIOGRA_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 10 June 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="TetracyclineAndOxyte.R1">Zimmerman HJ. Tetracyclines. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999. p. 599-602.<div><i>(Expert review of tetracycline and liver injury published in 1999; the tetracyclines cause two forms of drug induced liver injury, microvesicular fat and liver failure occurring after 4-10 days with high does of parenteral tetracyclines and an idiosyncratic liver injury that occurs with the oral agents, doxycycline causing a cholestatic and minocycline a hepatocellular injury which may be associated with autoimmune features).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R2">Moseley RH. Tetracyclines. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, p. 468.<div><i>(Expert review of tetracycline induced liver injury mentions that the hepatotoxicity of intravenous tetracycline is of historic interest only as it is no longer given parenterally; both doxycycline and minocycline have been associated with idiosyncratic liver injury).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R3">MacDougall C, Chambers HF. Tetracyclines and glycylcyclines. Protein synthesis inhibitors and miscellaneous antibacterial agents. In, Brunton LL, Chabner KA, Knollman KC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1521-6.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R4">Lepper MH, Wolfe CK, Zimmerman HJ, Cladwell ER Jr, Spies HW, Dowling HF. Effect of large doses of aureomycin on human liver. Arch Intern Med 1951; 88: 271-83.  [<a href="/pubmed/14856456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14856456</span></a>]<div><i>(Description of hepatotoxicity among 101 patients treated with aureomycin over a 30 month period; 7 had clinically apparent liver injury, all received high doses [&#x0003e;3 g] intravenously with onset of vomiting and mental changes followed by jaundice after 3-12 days; autopsy showed fatty liver).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R5">Rutenburg AM, Pinkes S. The hepatotoxicity of intravenous aureomycin. N Engl J Med 1952; 247: 797-800.  [<a href="/pubmed/13002619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13002619</span></a>]<div><i>(Serum bilirubin rose in some patients given iv aureomycin and some became &#x0201c;jaundiced&#x0201d;, but may have been partially an artifact of colorimetric method of bilirubin detection).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R6">Domz CA, McNamara DH, Holzapfel HF. Tetracycline provocation in lupus erythematosus. Ann Intern Med 1959; 50: 1217-26.  [<a href="/pubmed/13650436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13650436</span></a>]<div><i>(3 cases of apparent worsening of systemic lupus erythematosus after course of oxytetracycline for incurrent infection; no hepatic component mentioned).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R7">Ticktin HE, Zimmerman HJ. Hepatic dysfunction and jaundice in patients receiving triacetyloleandomycin. N Engl J Med 1962; 267: 964-8. Not in PubMed.<div><i>(50 &#x0201c;mental defectives or juvenile delinquents&#x0201d; were given triacetyloleandomycin [1 g orally per day] for 3-4 weeks with close monitoring, BSP retention increased in 54% by week 2, AST in 34%, ALT in 8%, 12% had symptoms, 4% jaundice; liver biopsy showed mixed cholestatic-hepatic picture in 2; rechallenge led to increases in AST and bilirubin in 2 within 1-2 days; all ultimately resolved).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R8">Schultz JC, Adamson JS Jr, Workman WW, Norman TD. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963; 269: 999-1004.  [<a href="/pubmed/14059734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14059734</span></a>]<div><i> (Initial dramatic report of acute fatty liver due to iv tetracycline; a rapidly fatal multisystem disease appeared in 6 pregnant women in their last trimester or early postpartum period after 3 to 5 days of relatively high doses of iv tetracycline; all developed jaundice [bilirubin 4.9-12.5 mg/dL] with mild AST [72-170 U/L] and Alk P [9-17 King Armstrong U/L] elevations, prolongation of protime, acidosis and renal dysfunction. Autopsy showed foamy hepatocytes, fat by oil red O stain and minimal hepatocyte necrosis).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R9">Tetracycline hepatotoxicity. Br Med J 1964; 2: 1545-6.  [<a href="/pmc/articles/PMC1817573/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1817573</span></a>] [<a href="/pubmed/14211749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14211749</span></a>]<div><i>(Editorial on the recently described syndrome of acute fatty liver in pregnant women receiving iv tetracycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R10">Dowling HF, Lepper MH. Hepatic reactions to tetracycline. JAMA 1964; 188: 307-9.  [<a href="/pubmed/14114004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14114004</span></a>]<div><i>(Review of literature on acute fatty liver due to tetracycline and recommendations on its use: avoiding doses &#x0003e;2 g/day and cautious use in women in last trimester of pregnancy).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R11">Horwitz ST, Marymont JH Jr. Fatal liver disease during pregnancy associated with tetracycline therapy. Report of a case. Obstet Gynecol 1964; 23: 826-9.  [<a href="/pubmed/14168241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14168241</span></a>]<div><i>(After complicated Caesarian and emergency hysterectomy with shock and bleeding, 41 year old woman received tetracycline given iv for 4 days, then orally to day 8; on day 10 she developed fever, acidosis and ileus, dying on day 16 with multiorgan failure and jaundice; autopsy showed fatty liver).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R12">Norman TD, Schultz JC, Hoke RD. Fatal liver disease following the administration of tetracycline. South Med J 1964; 57: 1038-42.  [<a href="/pubmed/14179316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14179316</span></a>]<div><i>(Further analysis of 6 cases of acute fatty liver after tetracycline in pregnant women with histological changes).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R13">Whalley PJ, Adams RH, Combes B. Tetracycline toxicity in pregnancy. Liver and pancreatic dysfunction. JAMA 1964; 189: 357-62.  [<a href="/pubmed/14160508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14160508</span></a>]<div><i>(Five cases of acute fatty liver with azotemia and pancreatitis after 4-17 days of iv or oral therapy 1-2 g/day: bilirubin 1.2-18.8 mg/dL; AST 34-780 U/L; Alk P 8.6-22 BU/L; 1 case fatal. The anicteric case had pancreatitis and was attributed to oral drug, but had fat on liver biopsy).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R14">Brewer T. Tetracycline hepatotoxicity. Br Med J 1965; 1: 995.  [<a href="/pmc/articles/PMC2165688/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2165688</span></a>] [<a href="/pubmed/14260641" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14260641</span></a>]<div><i>(Letter questioning role of tetracycline in acute fatty liver).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R15">Finn WF, Horwitz ST. Maternal death due to fatty metamorphosis of liver following tetracycline therapy. N Y State J Med 1965; 65: 662-7.  [<a href="/pubmed/14251580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14251580</span></a>]<div><i> (After Caesarian section, followed by hysterectomy and pneumonia, 41 year old woman received iv tetracycline for 4 days, followed by oral and then iv drug again, developing shock and jaundice; autopsy showed fatty liver without necrosis).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R16">Ichida F, Watanabe K, Ishiwara S, Inoue K, Tanabe Y. [A case of cholestatic jaundice due to tetracycline-triacetyloleandomycin] Nippon Naika Gakkai Zasshi 1965; 54:142-7. Japanese.  [<a href="/pubmed/5294320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5294320</span></a>]</div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R17">Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med 1965; 38: 359-77.  [<a href="/pubmed/14266828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14266828</span></a>]<div><i>(Classical clinical and histologic description of syndrome in 12 pregnant women, ages 19-31, given tetracycline for 3 to 12 days [total dose 1.5 to 14 g] after 16-39 weeks of pregnancy [bilirubin 12-19.8 mg/dL, ALT 24-210 U/L, AST 36-760 U/L, lactic acid high in 3/3 patients], 67% fatal, often accompanied by multiorgan failure, pancreatitis and shock).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R18">Tapp E, Carroll R. Tetracycline accumulation in toxic liver damage. J Pathol Bacteriol 1965; 89: 715-21.  [<a href="/pubmed/14320315" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14320315</span></a>]<div><i>(Animal studies showing accumulation of tetracycline in damaged hepatocytes, particularly with high levels of calcium).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R19">Winterling AN, Goldman RL. Hepatic and renal lesions in a case of tetracycline toxicity during long-term estrogen therapy after orchiectomy. Calif Med 1965; 102: 314-6.  [<a href="/pmc/articles/PMC1515729/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1515729</span></a>] [<a href="/pubmed/14291456" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14291456</span></a>]<div><i>(66 year old man post-orchiectomy for prostate cancer developed sudden onset of fever, lactic acidosis and mild jaundice [bilirubin 2.9 mg/dL] after 8 days of iv tetracycline [17 g], subsequently died after emergency laparotomy; autopsy showed fatty liver).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R20">Wruble LD, Ladman AJ, Britt LG, Cummins AJ. Hepatotoxicity produced by tetracycline overdosage. JAMA 1965; 192: 6-8.  [<a href="/pubmed/14262279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14262279</span></a>]<div><i>(56 year old woman with cecal volulus developed jaundice [bilirubin 7.8 mg/dL, AST 98 U/L, Alk P normal] 2 days after receiving 8 g of tetracycline, subsequently progressing to liver failure and death; autopsy showed fatty liver).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R21">Wruble LD, Cummins AJ. Tetracycline and fatty liver. Am J Dig Dis 1965; 10: 742-4.  [<a href="/pubmed/14316764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14316764</span></a>]<div><i>(Editorial on tetracycline induced acute fatty liver with discussion of mechanisms focusing on mitochondrial injury).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R22">Tetracyclines and the liver in pregnancy. Lancet 1966; 1: 357-8.  [<a href="/pubmed/4159865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4159865</span></a>]<div><i>(Editorial on the history of acute fatty liver of pregnancy, first described by Sheehan in 1940 and later linked to high dose iv tetracycline in pregnancy, but also in nonpregnant women and in men).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R23">Allen ES, Brown WE. Hepatic toxicity of tetracycline in pregnancy. Am J Obstet Gynecol 1966; 95: 12-8.  [<a href="/pubmed/5934994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5934994</span></a>]<div><i>(Prospective study done in 18 pregnant women who underwent liver biopsy and then were given 1-6 g of tetracycline [n=9] or oxytetracycline [n=9] intravenously for 3 days, at which time liver biopsy was repeated; increased AST [16 to 134 U/L] in 1, increase in fat in liver in most, but only detectable by oil red O stain, not by usual stains).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R24">Davis JS, Kaufman RH. Tetracycline toxicity. A clinicopathologic study with special reference to liver damage and its relationship to pregnancy. Am J Obstet Gynecol 1966; 95: 523-9.  [<a href="/pubmed/5939019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5939019</span></a>]<div><i>(6 cases of acute fatty liver, 1 man and 5 women [4 pregnant] given intravenous tetracycline for 9-10 days [3-6 g] [bilirubin 3-12.5 mg/dL, ALT 34-310 U/L], all acidotic and all died, autopsy showing fatty liver).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R25">Schiffer MA. Fatty liver associated with administration of tetracycline in pregnant and nonpregnant women. Am J Obstet Gynecol 1966; 96: 326-32.  [<a href="/pubmed/5919490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5919490</span></a>]<div><i>(Six cases of acute fatty liver from tetracycline, 2 in pregnancy at 34- and 40 weeks; 4 in nonpregnant women, but clinical course not described).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R26">Aach R, Kissane J eds. Clinicopathologic conference. A seventeen-year-old girl with fatty liver of pregnancy following tetracycline therapy. Am J Med 1967; 43: 274-83.  [<a href="/pubmed/6034958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6034958</span></a>]<div><i>(Clinicopathologic conference describing 17 year old pregnant woman who developed suspected pyelonephritis, was treated with im and oral tetracycline and 8 days later developed multiorgan failure, lactic acidosis and died despite induced delivery of a stillborn child).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R27">Lewis M, Schenker S, Combes B. Studies on the pathogenesis of tetracycline-induced fatty liver. Am J Dig Dis 1967; 12: 429-38.  [<a href="/pubmed/6026422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6026422</span></a>]<div><i>(Rats given high doses of iv tetracycline develop fat in liver with higher concentrations in pregnant rats, despite similar serum and hepatic concentrations of drug).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R28">Peters RL, Edmondson HA, Mikkelsen WP, Tatter D. Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases. Am J Surg 1967; 113: 622-32.  [<a href="/pubmed/6021433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6021433</span></a>]<div><i>(Classical description of clinical and histologic features of tetracycline induced acute fatty liver in nonpregnant patients; 6 nonpregnant women, ages 18-62, given iv tetracycline for 3-13 days [9-26 g] presenting with jaundice and lethargy; peak AST 52-960 U/L; bilirubin 2.7-7.4 mg/dL, often with complex and critical course, pancreatitis and renal failure, acidosis; fatty liver on autopsy).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R29">Damjanov I, Arnold R, Faour M. Tetracycline toxicity in a nonpregnant woman. JAMA 1968; 204: 934.  [<a href="/pubmed/5694615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5694615</span></a>]<div><i>(20 year old woman given iv tetracycline for 8 days after second of two gall bladder operations developed sudden onset of renal and hepatic failure [bilirubin 4.2 mg/dL, ALT 620 U/L], autopsy showed fatty liver and acute tubular necrosis).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R30">Hansen CH, Pearson LH, Schenker S, Combes B. Impaired secretion of triglycerides by the liver; a cause of tetracycline-induced fatty liver. Proc Soc Exp Biol Med 1968; 128: 143-6.  [<a href="/pubmed/5656682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5656682</span></a>]<div><i>(Tetracycline induces fatty liver in rats at least in part due to inhibition of hepatic secretion of triglycerides).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R31">Breitenbucher RB, Crowley LV. Hepatorenal toxicity of tetracycline. Minn Med 1970; 53: 949-55.  [<a href="/pubmed/5470245" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5470245</span></a>]<div><i>(Seven patients with acute fatty liver from tetracycline, arising 5-11 days after starting iv tetracycline [6-19 g] with complex courses, but fatty liver on autopsy in all).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R32">Kunin CM. Hepatorenal toxicity of tetracycline. Minn Med 1971; 5: 532-3.  [<a href="/pubmed/5564809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5564809</span></a>]<div><i>(Editorial in response to Breitenbucher questioning whether tetracycline was responsible for the clinical syndrome and attributing any injury to overdosage with tetracycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R33">Robinson MJ, Rywlin AM. Tetracycline-associated fatty liver in the male. Report of an autopsied case. Am J Dig Dis 1970; 15: 857-62.  [<a href="/pubmed/5459744" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5459744</span></a>]<div><i>(72 year old man given 10 days of iv tetracycline [30 g total] developed worsening liver injury followed by hepatic and renal failure and severe acidosis [bilirubin 6.8 mg/dL, AST 1550 KU/L, Alk P 15 KA U/L]; autopsy showed fatty liver, fatty vacuolization of renal tubular cells and pancreatitis).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R34">Breen KJ, Perkins KW, Mistilis SP, Shearman R. Idiopathic acute fatty liver of pregnancy. Gut 1970; 11: 822-5.  [<a href="/pmc/articles/PMC1553146/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1553146</span></a>] [<a href="/pubmed/5485832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5485832</span></a>]<div><i>(23 year old woman who survived acute fatty liver of pregnancy; onset day after spontaneous labor and stillborn delivery [bilirubin 7.9 mg/dL, Alk P 70 King Armstrong U/L, AST 67 U/L, prothrombin index 50%], liver biopsy showed fatty liver, improved with dextrose administration).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R35">Combes B, Whalley PJ, Adams RH. Tetracycline and the liver. Prog Liver Dis 1972; 4: 589-96.  [<a href="/pubmed/4569011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4569011</span></a>]<div><i>(Review of hepatotoxicity of tetracycline, including studies of pathogenesis).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R36">Pride GL, Cleary RE, Hamburger RJ. Disseminated intravascular coagulation associated with tetracycline-induced hepatorenal failure during pregnancy. Am J Obstet Gynecol 1973; 115: 585-6.  [<a href="/pubmed/4685515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4685515</span></a>]<div><i>(23 year old pregnant woman developed jaundice [bilirubin 7.8 mg/dL, AST 346 U/L, Alk P 38 U/L] and oliguria 2 weeks after 2 im injections of tetracycline who delivered a normal child, but then had self-limiting disseminated intravascular coagulation and hemolytic anemia after delivery).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R37">Whalley PJ, Combes B. Letter: Tetracycline toxicity. Am J Obstet Gynecol 1974; 118: 1149-51.  [<a href="/pubmed/4817657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4817657</span></a>]<div><i>(Letter in response to article by Pride et al. questioning the role of tetracycline because of dose and timing).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R38">Lloyd-Still JD, Grand RJ, Vawter GF. Tetracycline hepatotoxicity in the differential diagnosis of postoperative jaundice. J Pediatr 1974; 84: 366-70.  [<a href="/pubmed/4590715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4590715</span></a>]<div><i>(3 children [ages 2, 3 and 10 years; all girls] with chronic urinary tract disease developed jaundice and liver failure after surgery and several days of iv tetracycline; 2 autopsies and one liver biopsy showed fatty liver).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R39">Taneja OP, Grover NK, Thakur LC, Bhatia VN. Effects of blood levels of tetracycline and oxytetracycline on hepatic and renal functions in normal subjects. Chemotherapy 1974; 20: 201-11.  [<a href="/pubmed/4413117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4413117</span></a>]<div><i>(Mild increases in ALT and AST found in 20 healthy volunteers given oxytetracycline or tetracycline [1 g/day orally] for 5 days; no clinical symptoms or jaundice).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R40">Schenker S. Tetracycline hepatotoxicity. A review. Mater Med Pol 1976; 8: 173-6.  [<a href="/pubmed/790035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 790035</span></a>]</div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R41">Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 1981; 26: 135-41.  [<a href="/pubmed/7230149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7230149</span></a>]<div><i>(Two cases of acute fatty liver over a 15 year period and 60,000 deliveries; one woman received tetracycline for 3 days, the second had no history of its use, but had tetracycline detected in bony tissue suggestive of chronic use).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R42">B&#x000f6;cker R, Estler CJ, M&#x000fc;ller S, Pfandzelter C, Spachm&#x000fc;ller B. Comparative evaluation of the effects of tetracycline, rolitetracycline and doxycycline on some blood parameters related to liver function. Arzneimittelforschung 1982; 32: 237-41.  [<a href="/pubmed/7200783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7200783</span></a>]<div><i>(Minocycline caused a dose dependent rise in AST and increase in triglycerides, but no hepatic histological changes in mice; similar findings were previously reported with tetracycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R43">Carson JL, Strom BL, Duff A, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993; 119 (7 Pt 1): 576-83.  [<a href="/pubmed/8363168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8363168</span></a>]<div><i>(Case control study using Medicaid billing results between 1980-87 found 107 cases of hospitalization for unexplained hepatitis, odds ratios for erythromycin 5.2; sulfonamides 11.4; tetracyclines 5.2; total of 5 cases exposed to tetracycline, doxycycline or minocycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R44">Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994; 107: 1844-7.  [<a href="/pubmed/7958700" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7958700</span></a>]<div><i>(Two cases of severe and prolonged cholestatic hepatitis and bile duct paucity after oral tetracyclines; 37 year old woman developed jaundice 2 days after 3 day course of doxycycline with prolonged cholestasis [peak bilirubin 30 mg/dL], but ultimate recovery; 63 year old woman developed jaundice 6 weeks after a 2 week course of tetracycline [bilirubin 11.8 mg/dL, ALT 245 U/L], with prolonged jaundice [peak bilirubin 29.5 mg/dL) and persistence of enzyme elevations for &#x0003e;3 years [Alk P 631 U/L, ALT 97 U/L]).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R45">Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-8.  [<a href="/pubmed/1506809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1506809</span></a>]<div><i>(Adverse drug reaction reports between 1978 and 1987 in Denmark; no tetracycline is mentioned as a cause).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R46">Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years&#x02019; experience. N Z Med J 1996; 109: 315-9.  [<a href="/pubmed/8816722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8816722</span></a>]<div><i>(Adverse drug reaction reports identified 943 liver injuries over 21 years in New Zealand; triacetyloleandomycin accounted for 21 cases [2.1%] and minocycline for at least 4).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R47">Tham SN, Kwok YK, Chan HL. Cross-reactivity in fixed drug eruptions to tetracyclines. Arch Dermatol 1996; 132: 1134-5.  [<a href="/pubmed/8795565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8795565</span></a>]<div><i>(Among 9 Chinese patients with a fixed drug eruption due to tetracycline, all had recurrence on doxycycline and 3 on minocycline; no mention of liver involvement).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R48">Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133: 1224-30.  [<a href="/pubmed/9382560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9382560</span></a>]<div><i>(Review of toxicity of tetracyclines from literature and a Canadian database; minocycline had the highest rates of adverse events, but all were relatively safe: no lupus-like syndrome associated with doxycycline or tetracycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R49">Westermann GW, B&#x000f6;hm M, Bonsmann G, Rahn KH, Kisters K. Chronic intoxication by doxycycline use for more than 12 years. J Intern Med 1999; 246: 591-2.  [<a href="/pubmed/10620103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10620103</span></a>]<div><i>(38 year old man took large doses of doxycycline chronically and developed repeated bouts of mild jaundice [bilirubin 3.4-5.0 mg/dL, ALT 44-118 U/L, Alk P 466 U/L] and weakness, skin discoloration and heart block, resolving upon stopping).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R50">Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159: 493-7.  [<a href="/pubmed/10074958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10074958</span></a>]<div><i>(Case control study in 27,688 acne patients in UK database, risk of lupus increased 8.5 fold in minocycline treated patients, not with other tetracyclines, typically long term therapy; liver involvement not mentioned; more common in women, absolute risk low).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R51">Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23.  [<a href="/pubmed/15390328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15390328</span></a>]<div><i>(Among ~50,000 liver transplants done in the US between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, none of which were attributed to minocycline, doxycycline or tetracycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R52">Bj&#x000f6;rnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-1101.  [<a href="/pubmed/16165719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16165719</span></a>]<div><i>(Among 103 cases of fulminant drug induced liver injury reported to a Swedish registry between 1966 and 2002, one case was attributed to doxycycline, but no other tetracycline mentioned).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R53">Andrade RJ, Lucena MI, Fern&#x000e1;ndez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005; 129: 512-21.  [<a href="/pubmed/16083708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16083708</span></a>]<div><i>(Reports to a Spanish network found 461 cases of drug induced liver disease; no tetracycline was listed among the top 20 agents implicated [at least 5 cases]).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R54">Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005; 39: 64-7.  [<a href="/pubmed/15599214" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15599214</span></a>]<div><i>(Ten year experience of 96 patients with acute liver injury, 64 were due to viral hepatitis and 32 to drugs; minocycline accounted for 4 cases and ranked second in frequency [7 from amiodarone and 4 from amoxicillin/clavulanate]).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R55">Chamberlain MC, Schwarzenberg SJ, Akin EU, Kurth MH. Minocycline-induced autoimmune hepatitis with subsequent cirrhosis. J Pediatr Gastroenterol Nutr 2006; 42: 232-5.  [<a href="/pubmed/16456421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16456421</span></a>]<div><i>(15 year old boy developed signs of cirrhosis after 1 year of minocycline therapy [bilirubin 2.5 mg/dL, ALT 67-83 U/L, Alk P normal, ANA 1:40, anti-DNA positive], treated with 6-mercaptopurine and prednisone with only partial response and found to have cirrhosis on follow up liver biopsy).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R56">Bj&#x000f6;rnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006; 38: 33-8.  [<a href="/pubmed/16054882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16054882</span></a>]<div><i>(Survey of drug induced liver fatalities reported to WHO database between 1968-2003 revealed 4690 reports &#x02013; 89% from the US; the list of most 21 most commonly implicated drugs did not include a tetracycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R57">Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007; 157: 540-6.  [<a href="/pubmed/17596147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17596147</span></a>]<div><i>(Analysis of UK database on 97,694 subjects with acne, 25% received minocycline, 16% doxycycline and 45% other tetracyclines. Hazard ratio for lupus-like syndrome was 3.11 for minocycline; no increased risk or association with doxycycline or other tetracyclines).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R58">Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 2007; 32: 483-7.  [<a href="/pubmed/17875115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17875115</span></a>]<div><i>(Analysis of 2 years of Medicaid claims in California found 3377 cases of &#x0201c;hepatotoxicity&#x0201d;; 20 had received tetracycline &#x0003c;45 days before onset; only 4 controls had: adjusted odds ratio 3.7; not elevated for doxycycline; this despite safety record of oral tetracyclines and known hepatotoxicity of doxycycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R59">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i> (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, minocycline accounted for 3 cases, doxycycline for 3 cases and tetracycline was listed as a secondary possible cause for one).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R60">Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol 2009; 43: 787-90.  [<a href="/pubmed/19262406" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19262406</span></a>]<div><i>(3 cases of minocycline hepatotoxicity; 16 year olds with onset of jaundice 2, 13 and 24 months after starting minocycline for acne [bilirubin 19.6, 9.1 and 9.5 mg/dL, ALT 1282, 2306 and 2056 U/L, ANA 1:160-1:640], liver biopsies showing hepatitis and fibrosis; all treated with corticosteroids, 2 requiring prolonged therapy).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R61">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-8.  [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database containing 9036 hepatic adverse drug reactions in children includes 117 cases attributed to minocycline, but no other tetracycline listed in the top 40 causes).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R62">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-404.  [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(313 cases of drug induced liver injury were seen over a 12 year period at a large hospital in Bangalore, India; none were due to tetracyclines).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R63">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury and 25 to antituberculosis agents, including 15 to isoniazid alone [ranking first], 6 to isoniazid combined with other agents, 3 to rifampin and pyrazinamide, and 1 to dapsone).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R64">Leitner JM, Graninger W, Thalhammer F. Hepatotoxicity of antibacterials: Pathomechanisms and clinical. Infection 2010; 38: 3-11.  [<a href="/pubmed/20107858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20107858</span></a>]<div><i>(Review of hepatotoxicity of antibiotics; mentions that hepatotoxicity from oral tetracycline is rare ~1.5 cases per million prescriptions, whereas minocycline has been associated with either an immediate reaction with eosinophilia, dermatitis and enzyme elevations or a delayed autoimmune hepatitis-like syndrome).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R65">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to a tetracyclinel).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R66">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, 37 of which were attributed to an antibiotic, but none to a tetracycline).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R67">Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R, et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol 2015; 79: 988-99.  [<a href="/pmc/articles/PMC4456131/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4456131</span></a>] [<a href="/pubmed/25444550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25444550</span></a>]<div><i> (Among 76 inpatients with hepatitis of uniknown cause enrolled in a prospective case-cohort surveillance study between 2002 and 2011, one was attributed to doxycycline, but no other tetracycline was implicated).</i></div></div></li><li><div class="bk_ref" id="TetracyclineAndOxyte.R68">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 323 [36%] were attributed to antibiotics including 28 [3%] to minocycline and 4 [0.4%] to doxycycline).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK547920</span><span class="label">PMID: <a href="/pubmed/31643255" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643255</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Tesamorelin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Tetracyclines/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK547920&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK547920/?report=reader">PubReader</a></li><li><a href="/books/NBK547920/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK547920" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK547920" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Tetracycline. [Updated 2017 Jun 10].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK547920/pdf/Bookshelf_NBK547920.pdf">PDF version of this page</a> (151K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(tetracycline/AE+OR+oxytetracycline/AE)+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Tetracycline: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=tetracycline+OR+oxytetracycline" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Tetracycline: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4855968" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4855968" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4855968" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643186" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Eravacycline</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Eravacycline<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/1985047" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline.</a><span class="source">[Gastroenterology. 1991]</span><div class="brieflinkpop offscreen_noflow">Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichtman SN, Keku J, Schwab JH, Sartor RB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gastroenterology. 1991 Feb; 100(2):513-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643226" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Omadacycline</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Omadacycline<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643616" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sarecycline</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sarecycline<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26640164" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Bicyclol attenuates tetracycline-induced fatty liver associated with inhibition of hepatic ER stress and apoptosis in mice.</a><span class="source">[Can J Physiol Pharmacol. 2016]</span><div class="brieflinkpop offscreen_noflow">Bicyclol attenuates tetracycline-induced fatty liver associated with inhibition of hepatic ER stress and apoptosis in mice.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Yao XM, Li Y, Li HW, Cheng XY, Lin AB, Qu JG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Can J Physiol Pharmacol. 2016 Jan; 94(1):1-8. Epub 2015 Sep 22.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643255" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643255" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60469521ce712d3c9ca49a8d">Tetracycline - LiverTox</a><div class="ralinkpop offscreen_noflow">Tetracycline - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:20:33-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D98FA0466D2110000000008F50292&amp;ncbi_session=CE8D98FA04695201_2293SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547920%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK547920&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK547920/&amp;ncbi_pagename=Tetracycline - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D98FA04695201_2293SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>